Understanding the Adverse Events of PARP Inhibitors
By Bobbie J. Rimel, MD
PUBLISHED WEDNESDAY, DECEMBER 31, 1969
There are three adverse events (AEs) that are common to all the PARP inhibitors used to treat ovarian cancer: fatigue, anemia, and nausea, explained Bobbie J. Rimel, MD, an assistant professor of obstetrics and gynecology at Cedars-Sinai.
However, there are also AEs that tend to be more common for certain agents. For example, niraparib (Zejula) is more likely to cause high blood pressure; rucaparib (Rubraca) is more likely to affect kidney function; and olaparib (Lynparza) is more likely to cause gastrointestinal issues.
You must log in to use this feature, please click here to login.